PASTA: Paediatric Arteriopathy Steroid Aspirin Project

Sponsor

Centre Hospitalier Universitaire de Saint Etienne (Other)

Overall Status

Not yet recruiting

CT.gov ID

NCT03249844

Collaborator

Ministry of Health, France (Other)

Enrollment

Locations

Arms

Anticipated Duration (Months)

Patients Per Site

0.1

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Arterial ischemic stroke (AIS) is a devastating condition, affecting 1.6-5/100,000 children/year. Although their outcome is different, children with stroke do not recover better than adults, with at least 2/3 suffering long term sequels such as developmental (motor, global intellectual, language...) and behavioral disabilities, epilepsy, and low adaptative and academic skills...

Stenotic cerebral arteriopathy is identified as AIS etiology in 60-80% of previously healthy children and the course of this arteriopathy is the strongest predictor of recurrent events. 30-40% of these children have a focal unilateral cerebral arteriopathy (FCA). Childhood FCA is suspected to be an inflammatory vessel wall pathology triggered by varicella and other (viral) infections. As recurrences occur for the great majority in the first 6 months after the index event, aspirin 5 mg/kg/day is recommended for at least 18 months to 2 years.

As there is a rational for using immunomodulatory drugs at the acute stage of FCA, immunotherapies are currently used by neuropaediatricians in AIS, mainly as steroids for children with stenosing arteriopathies. However, due to weak evidences, the literature cannot either encourage or discourage this practice.

The long term course of children with FCA is only approach to date by retrospective studies and controversies about outcome remain (for example, the recurrence risk on antithrombotic treatment varies notably from quasi zero to 25%). And finally, it is shown in childhood stroke, as well as in the global field of longstanding impairment, that parental and medical points of view do not match consistently. Longitudinal studies are needed to deserve this familial approach.

Condition or Disease	Intervention/Treatment	Phase
Arterial Ischemic Stroke	Drug: Methylprednisolone + prednisolone	Phase 3

Study Design

Study Type:

Interventional

Anticipated Enrollment :

40 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

Single (Outcomes Assessor)

Masking Description:

The outcome assessor don't know patient treatment

Primary Purpose:

Treatment

Official Title:

High Dose Steroids in Children With Stroke and Unilateral Focal Arteriopathy: Paediatric Arteriopathy Steroid Aspirin (PASTA) Project. A Multicentre Randomized Trial.

Anticipated Study Start Date :

Sep 1, 2022

Anticipated Primary Completion Date :

Dec 31, 2027

Anticipated Study Completion Date :

Dec 31, 2027

Arms and Interventions

Arm	Intervention/Treatment
Experimental: experimental group Children will be treated by methylprednisolone + prednisolone and standard of care	Drug: Methylprednisolone + prednisolone The experimental intervention consists of 5 consecutive days Methylprednisolone at a daily single intravenous dose of 20 mg/kg body-weight (max 1 g/day) followed by a 4-week course of tapering Prednisolone given at a daily single oral dose in the morning: week 1 and 2, oral Prednisolone 1 mg/kg/day (max 40 mg/day), , week 3 and 4, oral Prednisolone 0,5 mg/kg/day (max 20 mg/day),
No Intervention: control group Children will be treated by standard of care alone

Arm

Intervention/Treatment

Experimental: experimental group

Children will be treated by methylprednisolone + prednisolone and standard of care

Drug: Methylprednisolone + prednisolone

The experimental intervention consists of 5 consecutive days Methylprednisolone at a daily single intravenous dose of 20 mg/kg body-weight (max 1 g/day) followed by a 4-week course of tapering Prednisolone given at a daily single oral dose in the morning: week 1 and 2, oral Prednisolone 1 mg/kg/day (max 40 mg/day), , week 3 and 4, oral Prednisolone 0,5 mg/kg/day (max 20 mg/day),

No Intervention: control group

Children will be treated by standard of care alone

Outcome Measures

Primary Outcome Measures

Time to recovery up to 12 months [Up to 12 months]
Evaluate of time to recovery up to 12 months by score paediatric Recurrence and Recovery Questionnaire (RRQ )

Secondary Outcome Measures

Improvement of functional outcome by face-to-face visits [Months:1,6,12, 24 and 36]
Evaluate of Improvement of functional outcome by face-to-face visits by score Paediatric Stroke Outcome Measure (PSOM), modified Rankin Scale (mRS) and Vineland Adaptive Behaviour Scale (VABS).
Arteriopathic course along time [Months: 1, 6, 24]
Evaluate of Arteriopathic course along time by comparison between magnetic resonance (MR) arteriography and initial imaging.
Recurrence of stroke, epilepsy, neurological and developmental sequels, and academic achievement [Months: 1, 3, 6,12, 24 and 36]
Evaluate recurrence of stroke, epilepsy, neurological and developmental sequels, and academic achievement at 6, 12, 24 and 36 months. Neurological outcome will be assessed by standard clinical examination: motricity, sensibility, coordination, oculomotricity and visual field, cranial nerves…
Outcome by age group [Months 72]
Evaluate outcome by age group. All endpoints will be stratified for the whole cohort by the following age group: 0.5-3 years; 3-6 years; 6-10 years and ≥10 years. This will be done in a centrally-manner at Clinical Trials Unit (CTU) Bern.
Familial impact [Months 72]
Evaluate of familial impact by Alberta Perinatal Stroke Parental Outcome Measure (APSOM) and indepth interview through semi-structured interviews. The objective is to report the lived experience of parents whose child was included in the study.
Number of serious adverse events [Months 72]
Analysis of number of serious adverse events and their cause, consequence.

Eligibility Criteria

Criteria

Ages Eligible for Study:

6 Months to 15 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

-- Aged 6 months to <15 years

AIS ≤ 48 hours
Newly acquired focal neurological deficit with confirmation by magnetic resonance imaging (MRI) of ischaemic lesion in an arterial territory corresponding with the clinical features (definition of Arterial ischemic stroke).
Magnetic resonance arteriography showing unilateral proximal stenosis or irregularities of the corresponding carotid trifurcation (i.e. terminal carotid and/or M1-M2 and/or A1 segments) or of the posterior circulation (P1-P2 segments).
No evidence of an underlying systemic disorder (e.g. lupus erythematodes) explaining the features.
Informed and signed consent of parents or legal guardians.
French Social Security (Sécurité sociale; i.e. national health coverage) affiliation

Exclusion Criteria:

Children with secondary central nervous system angiitis due to infections (meningitis, endocarditis, borreliosis), rheumatic or other systemic inflammatory diseases (e.g. lupus erythematodes). These children are already under immune suppression or need other co-medications regarding their underlying disease.
Children with known syndromal and/or genetic vasculopathies such as phaces syndrome, Neurofibromatosis type 1, trisomy 21.
Children with moyamoya or sickle cell disease.
Children with a progressive large to medium vessel childhood primary angiitis of the central nervous system with two out of the following three criteria : Children with progressive neurocognitive dysfunction; Children with bilateral lesions/vessel involvement; Children with distal arterial stenosis (beyond the M2, A1 or P2 segment).
Children already on steroid treatment at disease onset or with a contraindication to receive steroid treatment (e.g. congenital or acquired immunodeficiency).
Children with delayed diagnosis ≥3 days as treatment start is not allowed to be more ≥5 day-delayed.
Contraindications to steroids (see also summary of product characteristics in chapter 1.1) and notably: Not-manageable infectious, hydro-electrolytic or metabolic (e.g. diabetes mellitus) disorders, or elevated blood pressure, Serious behavioral disorders, Current vaccination with live or attenuated live strains, Allergy/sensibility to any ingredient, Association with some medications such as antiarrhythmic drugs.

Contacts and Locations

Locations

	Site	City	Country	Postal Code
1	CHU Angers	Angers	France	49100
2	CHU Lyon - Hôpital Femme Mère Enfant	Bron	France	69677
3	APHP - Hôpital Bicêtre	Le Kremlin-Bicêtre	France	94270
4	APHP - Hôpital Necker-Enfants malades	Paris	France	75015
5	Chu Saint-Etienne	Saint-Étienne	France	42055